据古巴媒体9日报道，古巴分子免疫中心研制并注册了一种新的治疗肺癌的疫苗RACOTUMOMAB，这是该中心继CIMAvaxEGF之后研制出的第二种肺癌疫苗，也是该中心2012年最大的科研成果。

According to the Cuban media reported on 9th, July,Cuba molecular and immunological center developed and registered a new treatment for lung cancer vaccine RACOTUMOMAB,This is the center after the CIMAvaxEGF developed the second kind of lung cancer vaccine,Is the center in 2012, the biggest achievements in scientific research.

　　古巴分子免疫中心主任阿古斯丁·拉赫说，新疫苗RACOTUMOMAB使用方便，在临床试验中显示出“激动人心”的效果，并在欧洲肿瘤内科学会大会上获得广泛认可，其研究论文随后发表于《柳叶刀肿瘤学》杂志上。

Cuba, director of the center for molecular and immunological agus butyl · lage said,The new vaccine RACOTUMOMAB easy to use,In clinical trials show"exciting"effect,And in Europe the tumor medical society conference be widely recognized,The research papers published in later[The lancet oncology]magazine.

　　拉赫表示，RACOTUMOMAB今年将开始批量生产，这将使更多的古巴肺癌患者获得及时的干预和治疗，它在海外的注册也已进入日程。

Lage said,RACOTUMOMAB this year will begin to batch production,This will make more Cuba lung cancer get timely intervention and treatment,It in the overseas registered and has entered into the schedule.

　　RACOTUMOMAB的研发使古巴继续在世界范围内的肺癌治疗领域保持领先地位。古巴是目前世界上唯一一个研究开发出两种肺癌疫苗的国家。

RACOTUMOMAB development make Cuba to continue in the world within the scope of the lung cancer therapeutic areas keep ahead.Cuba is currently the world's only a research developed two kinds of lung cancer vaccine country.

　　用于治疗非小细胞肺癌的CIMAvaxEGF疫苗在古巴已进行临床试验，并已获中国国家食品药品管理局的批准在中国医学科学院进行临床试验。

Used in the treatment of non-small cell lung cancer CIMAvaxEGF vaccine clinical trials in Cuba has,And has been China's state food and drug administration approved by the Chinese academy of medical sciences in clinical trials.

　　CIMAvaxEGF肺癌疫苗是世界上唯一注册的此类药品。(记者林如萱)

CIMAvaxEGF lung cancer vaccine is the world's only registered of these drugs.(Reporter Lin as xuan)